Product News
Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing
The award comes after Avacta obtained regulatory approval for the Lateral Flow Test
The award comes after Avacta obtained regulatory approval for the Lateral Flow Test
Affimer technology shown to offer key performance benefits compared to antibodies and other technologies in this application
Affimer technology will potentially provide significant advantages over antibody fragment technology currently used in CAR-T cell modification
Avacta collaborates to develop rapid tests to differentiate between viral and bacterial infections and to differentiate bacterial strains